Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CALCIPOTRIOL
Clear Pharmacy
D05AX02
CALCIPOTRIOL
50 Micrograms/g
Cream
Product subject to prescription which may not be renewed (A)
Other antipsoriatics for topical use
Authorised
2010-12-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dovonex 50 micrograms/g Cream. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains 50 micrograms of calcipotriol (as the hydrate). Excipient(s): Cetostearyl alcohol For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cream. _Product imported from UK:_ Soft white cream. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dovonex Cream is indicated for the topical treatment of plaque psoriasis (psoriasis vulgaris). Dovonex cream may also be used in combination with topical corticosteroids. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS The cream should be applied to the affected area once to twice daily. Twice daily application of the cream is often preferred initially. Application of the cream can be reduced to once daily when appropriate. Maximum weekly dose should not exceed 100g. Dovonex Cream in combination with corticosteroids (e.g. administration of Dovonex in the morning and steroid in the evening) is effective and well tolerated. CHILDREN _Over 12 years_ Dovonex Cream should be applied to the affected area twice daily. Maximum weekly dose should not exceed 75g. _Aged 6 to 12 years_ Dovonex Cream should be applied to the affected area twice daily. Maximum weekly dose should not exceed 50g. _Under 6 years_ There is limited experience of the use of Dovonex Cream in this age group. A maximum safe dose has not been established. There is no experience of use of Dovonex in combination with other psoriasis therapies in children. 4.3 CONTRAINDICATIONS Known hypersensitivity to any of the ingredients. Due to the content of calcipotriol, Dovonex is contraindicated in patients with known disorders of calcium metabolism. IRISH MEDICINES BOARD _______________________________________________________ Read the complete document